Large Scale Biology Corporation Announces the Issuance of Thirteen New U.S. Patents and Several New Allowances
The 13 new issuances comprise 3 patents on vectors for gene expression in plant as well as animal host systems, 2 patents on plant-based bioprocessing methods, and 2 on vaccines and methods to manufacture vaccines. Simultaneously announced was the issuance of 2 U.S. patents to LSBC on the Company's unique gene shuffling and molecular evolution technology (GRAMMR(TM)), as well as 4 more patents (3 newly issued) to LSBC's subsidiary company, Predictive Diagnostics, Inc. (PDI), on methods for biomarker discovery and diagnostics.
In addition to these issued patents, LSBC has received notice of allowance for three additional applications. Application 10/061,969, entitled "Microarrays and Their Manufacture by Slicing," describes a unique method of manufacturing microarray chips, with utility in the fields of genomics and proteomics. Application 10/280,725, entitled "Recombinant Viral Nucleic Acids," describes the application of LSBC's transient, virus-driven gene expression technology (GENEWARE®) to animal cells. Lastly, application 10/193,142, entitled "Production of a Parvovirus Vaccine in Plants as Viral Coat Protein Fusions," describes methods and compositions to produce animal health vaccines using efficient plant virus-based expression technology.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.